

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. and Sandoz Canada Inc. that the shortages for Apo-Feno-Super 160 mg Tablet (DIN 02246860) and Sandoz Fenofibrate S 160 mg Tablet (DIN 02288052) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 30, 2019**.

FENOFIBRATE

160 MG TABLET

00002246860	APO-FENO-SUPER	APX	\$ 0.2723
00002288052	SANDOZ FENOFIBRATE S	SDZ	\$ 0.2723
00002241602	LIPIDIL SUPRA	BGP	\$ 1.3362

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril 5 mg Tablet (DIN 02248499) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 14, 2019**.

QUINAPRIL

5 MG TABLET

00002248499	APO-QUINAPRIL	APX	\$ 0.2321
00001947664	ACCUPRIL	PFI	\$ 0.9742

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril 10 mg Tablet (DIN 02248500) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 14, 2019**.

QUINAPRIL

10 MG TABLET

00002248500	APO-QUINAPRIL	APX	\$ 0.2321
00001947672	ACCUPRIL	PFI	\$ 0.9742

... continued from previous page

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril 40 mg Tablet (DIN 02248502) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 14, 2019**.

QUINAPRIL

40 MG TABLET

00002248502	APO-QUINAPRIL	APX	\$ 0.2321
00001947699	ACCUPRIL	PFI	\$ 0.9742

Alberta Blue Cross has been advised by Actavis Pharma Company that the shortage for Act Dextroamphetamine SR 15 mg Sustained-Release Capsule (DIN 02448327) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 16, 2019**.

DEXTROAMPHETAMINE SULFATE

15 MG SUSTAINED-RELEASE CAPSULE

00002448327	ACT DEXTROAMPHETAMINE SR	APH	\$ 0.9898
00001924567	DEXEDRINE	PAL	\$ 1.1131

Product supply shortage addressed for *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Alberta Blue Cross has been advised by Pendopharm Inc. that the shortage for Cromolyn 2% Ophthalmic Solution (DIN 02009277) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 17, 2019**.

SODIUM CROMOGLYCAT

2 % OPHTHALMIC SOLUTION

00002009277	CROMOLYN	PPH	\$ 0.9500
00002230621	OPTICROM	ALL	\$ 1.0130

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.812 2019/09

